ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO

被引：0
|
作者：
TONG, AW
SU, D
MUES, G
SOLANO, M
STONE, MJ
机构：
[1] BAYLOR UNIV,BAYLOR SAMMONS CANC CTR,MED CTR,DALLAS,TX
[2] BAYLOR RES INST,M CROWLEY LAB,DALLAS,TX
来源：
BLOOD | 1994年 / 84卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A170 / A170
页数：1
相关论文
共 50 条
  • [1] ANTI-CD40 ANTIBODY-BINDING MODULATES HUMAN MULTIPLE-MYELOMA CLONOGENICITY IN-VITRO
    TONG, AW
    ZHANG, BQ
    MUES, G
    SOLANO, M
    HANSON, T
    STONE, MJ
    BLOOD, 1994, 84 (09) : 3026 - 3033
  • [2] CD40 and the effect of anti-CD40-binding on human multiple myeloma clonogenicity
    Tong, AW
    Stone, MJ
    LEUKEMIA & LYMPHOMA, 1996, 21 (1-2) : 1 - 8
  • [3] Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma
    Tai, YT
    Li, XF
    Tong, X
    Santos, D
    Otsuki, T
    Catley, L
    Tournilhac, O
    Podar, K
    Hideshima, T
    Schlossman, R
    Richardson, P
    Munshi, NC
    Luqman, M
    Anderson, KC
    CANCER RESEARCH, 2005, 65 (13) : 5898 - 5906
  • [4] A fully human antagonist anti-CD40 antibody triggers significant antitumor activity against human multiple myeloma
    Tai, YT
    Li, XF
    Tong, X
    Catley, L
    Santos, D
    Tournilhac, O
    Schlossman, R
    Richardson, P
    Munshi, NC
    Luqman, M
    Anderson, KC
    BLOOD, 2004, 104 (11) : 663A - 664A
  • [5] A phase I humanized Anti-CD40 monoclonal antibody (SGN-40) in patients with multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Harrop, KL
    McDonald, M
    Drachman, JG
    BLOOD, 2005, 106 (11) : 723A - 723A
  • [6] Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: Clinical implications
    Tai, YT
    Catley, LP
    Mitsiades, CS
    Burger, R
    Podar, K
    Shringpaure, R
    Hideshima, T
    Chauhan, D
    Hamasaki, M
    Ishitsuka, K
    Richardson, P
    Treon, SP
    Munshi, NC
    Anderson, KC
    CANCER RESEARCH, 2004, 64 (08) : 2846 - 2852
  • [7] Phase I trial of a humanized anti-CD40 monoclonal antibody (SGN-40) in the treatment of multiple myeloma.
    Hussein, MA
    Berenson, JR
    Niesvizky, R
    Munshi, NC
    Anderson, KC
    Ryan, KL
    Baumgartner, KT
    Miller, DM
    Drachman, JG
    McDonald, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 580S - 580S
  • [8] The humanized Anti-CD40 antibody SGN-40 inhibits tumor growth in LAGκ-1A, a CD40+ mouse model of human multiple myeloma.
    Campbell, Richard A.
    Gordon, Melinda S.
    Sanchez, Eric
    Chen, Haiming
    Turker, Lauren
    Trac, Olivia
    Li, Mingjie
    Pang, Shen
    Bonavida, Benjamin.
    Said, Jonathan
    Drachman, Jonathan G.
    Berenson, James R.
    BLOOD, 2006, 108 (11) : 1000A - 1000A
  • [9] A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma
    Hussein, Mohamad
    Berenson, James R.
    Niesvizky, Ruben
    Munshi, Nikhil
    Matous, Jeffrey
    Sobecks, Ronald
    Harrop, Kate
    Drachman, Jonathan G.
    Whiting, Nancy
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (05): : 845 - 848
  • [10] A chimeric humanized anti-CD40 antibody renders human multiple myeloma (MM) cells refractory to the mitogenic and protective effects of IL-6
    Tai, YT
    Mitsiades, CS
    Catley, LP
    Burger, R
    Podar, K
    Shringarpure, R
    Hideshima, T
    Chauhan, D
    Hamasaki, M
    Ishitsuka, K
    Richardson, P
    Munshi, N
    Treon, S
    Anderson, K
    BLOOD, 2003, 102 (11) : 935A - 935A
12345